TLRY on Nasdaq

Tilray

North American pharmaceuticals, brewing and cannabis company

Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand,Latin America, with growing facilities in Germany, Portugal and the United Kingdom. In December 2020, the company announced a merger with Aphria, and now operates under the Tilray name and its ticker symbol on NASDAQ and the Toronto Stock Exchange.3 Its shares trade on Nasdaq under the symbol TLRY.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$915.5MRevenue, fiscal 20265
-$121.4MNet income, fiscal 20265
2013Founded1

Compare with USANA Health Sciences, Trulieve Cannabis Corp. or Curaleaf, or pick any stock.

  • TickerTLRY on Nasdaq1
  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersNanaimo1
  • Websitewww.tilray.com
  • Legal formDelaware corporation1
  • Business address445 Park Avenue, New York, Ny 100226
  • Filer categoryLarge accelerated filer6
  • LEI549300Y4V60733TO14784
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 67259144

Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand,Latin America, with growing facilities in Germany, Portugal and the United Kingdom.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

28.4%Gross margin5
-6.9%Operating margin5
-13.3%Net margin5
11.5%Revenue growth, 20265
-7.5%Return on equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Distribution Business brought in 36% of the revenue Tilray broke down this way in fiscal 2026.

  1. Distribution Business$327.2M536%up 21% from 2025
  2. Cannabis$268.3M529%up 8% from 2025
  3. Beverage Alcohol Business$254.0M528%up 6% from 2025
  4. Wellness Business$65.9M57%up 9% from 2025
Business segments by year
Business segments202420252026
Distribution Business$258.7M$271.2M$327.2M
Cannabis$272.8M$249.0M$268.3M
Beverage Alcohol Business$202.1M$240.6M$254.0M
Wellness Business$55.3M$60.5M$65.9M

Regions

EMEA brought in 49% of the revenue Tilray broke down this way in fiscal 2026.

  1. EMEA$445.7M549%up 38% from 2025
  2. United States$242.4M526%down 11% from 2025
  3. Canada$215.7M524%up 1% from 2025
  4. Rest Of World$11.7M51%up 3% from 2025
Regions by year
Regions202420252026
EMEA$296.4M$323.4M$445.7M
United States$233.1M$273.7M$242.4M
Canada$243.7M$212.9M$215.7M
Rest Of World$15.6M$11.4M$11.7M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue72¢$655.0M
  • Research and development0¢$361.0K
  • Other costs23¢$213.1M
  • Interest3¢$29.9M
  • Income tax2¢$17.1M

Out of $915.5M in revenue.5 The company lost money this year.

Financial statements

Revenue91011125$915.5M in 2026+448% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $167.0M$167.0M20192020: $210.5M$210.5M2020+26%2021: $513.1M$513.1M2021+144%2022: $628.4M$628.4M2022+22%2023: $627.1M$627.1M2023−0%2024: $788.9M$788.9M2024+26%2025: $821.3M$821.3M2025+4%2026: $915.5M$915.5M2026+11%
Gross profit91011125$260.4M in 2026
-$100.0M0$100.0M$200.0M$300.0M2019: -$23.5M-$23.5M20192020: $24.7M$24.7M20202021: $123.2M$123.2M2021+400%2022: $116.8M$116.8M2022−5%2023: $147.0M$147.0M2023+26%2024: $223.4M$223.4M2024+52%2025: $240.6M$240.6M2025+8%2026: $260.4M$260.4M2026+8%
Operating income91011125-$63.0M in 2026−79% since 2019
-$3.0B-$2.0B-$1.0B02019: -$304.1M-$304.1M20192020: -$201.1M-$201.1M2020−34%2021: -$132.2M-$132.2M2021−34%2022: -$610.4M-$610.4M2022+362%2023: -$1.4B-$1.4B2023+124%2024: -$174.7M-$174.7M2024−87%2025: -$2.3B-$2.3B2025+1206%2026: -$63.0M-$63.0M2026−97%
Net income91011125-$121.4M in 2026−62% since 2019
-$3.0B-$2.0B-$1.0B02019: -$321.2M-$321.2M20192020: -$271.1M-$271.1M2020−16%2021: -$367.4M-$367.4M2021+36%2022: -$476.8M-$476.8M2022+30%2023: -$1.5B-$1.5B2023+205%2024: -$245.0M-$245.0M2024−83%2025: -$2.2B-$2.2B2025+793%2026: -$121.4M-$121.4M2026−94%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2026-05-312025-05-312024-05-31
Net revenue$915.5M$821.3M$788.9M
Cost of goods sold$655.0M$580.7M$565.6M
Gross profit$260.4M$240.6M$223.4M
General and administrative$203.6M$167.3M$167.4M
Selling$49.3M$56.0M$37.2M
Amortization$19.6M$88.6M$84.8M
Marketing and promotion$42.3M$37.0M$41.9M
Research and development$361.0K$284.0K$635.0K
Change in fair value of contingent consideration-$15.0M$0-$15.8M
Asset, Impairment Loss$0$2.1B$0
Other than temporary change in fair value of convertible notes receivable$0$21.7M$42.7M
Litigation costs, net of recoveries$3.9M$17.3M$8.3M
Restructuring costs$13.1M$34.3M$15.6M
Transaction costs (income), net$6.3M$4.5M$15.5M
Total operating expenses$323.5M$2.5B$398.1M
Operating loss-$63.0M-$2.3B-$174.7M
Interest expense, net-$23.7M-$30.0M-$36.4M
Nonoperating Income (Expense)-$1.4M$10.3M-$37.8M
Loss before income taxes-$88.1M-$2.3B-$249.0M
Income tax expense (recovery), net$17.1M-$121.0M-$26.6M
Net loss-$105.2M-$2.2B-$222.4M
Stockholders of Tilray Brands, Inc.-$121.4M-$2.2B-$245.0M
Non-controlling interests-$16.2M-$5.4M-$22.6M
Foreign currency translation gain (loss)$207.0K$430.0K$3.1M
Comprehensive loss-$105.0M-$2.2B-$219.3M
Stockholders of Tilray Brands, Inc.-$122.6M-$2.2B-$241.9M
Non-controlling interests$17.6M$5.4M$22.6M
Weighted average number of common shares - basic(1) (in shares)111.8M shares89.0M shares74.3M shares
Weighted average number of common shares - diluted(1) (in shares)111.8M shares89.0M shares74.3M shares
Net loss per share - basic(1) (in dollars per share)-$1.09-$24.56-$3.30
Net loss per share - diluted(1) (in dollars per share)-$1.09-$24.56-$3.30

Compare Tilray with another company

Corporate structure

Tilray sits at the top of its group. 31 entities, 16 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Tilray

  • Tilray Nanaimo, British Columbia, Canada
    • HEXO Corp. Stake · Gatineau, Quebec, Canada
    • MedMen Stake · Los Angeles
    • 14U Pharma GmbH Subsidiary · Germany
    • ABP S.A. Subsidiary · Argentina
    • Aphria Germany GmbH fka Nuuvera Deutschland GmbH Subsidiary · Germany
    • Aphria RX GMBH fka Deutschland GmbH Subsidiary · Germany
    • Aphria Wellbeing GmbH Subsidiary · Germany
    • BrewDog Brewing Australia Pty Ltd. Subsidiary · Australia
    • CC Pharma GmbH Subsidiary · Germany
    • Colcanna S.A.S. Subsidiary · Colombia
    • Eezy Group Ltd. Subsidiary · United Kingdom
    • Hampstead International, Inc. Subsidiary · Barbados
    • High Park Botanicals B.V. Subsidiary · Netherlands
    • High Park Holdings B.V. Subsidiary · Netherlands
    • Lyphe Clinic Ltd. Subsidiary · United Kingdom
    • Lyphe Dispensary Ltd. Subsidiary · United Kingdom
    • Lyphe Subco Ltd. Subsidiary · United Kingdom
    • Marigold Projects Limited Subsidiary · Jamaica
    • Nuuvera Israel Limited Subsidiary · Israel
    • Solana Life Group, S de R.L. Subsidiary · Panama
    • Tilray Australia New Zealand Pty. Ltd. Subsidiary · Australia
    • Tilray Beverages UK Limited Subsidiary · United Kingdom
    • Tilray Brands UK, Ltd. fka Tilray Wellness UK Ltd. Subsidiary · United Kingdom
    • Tilray Deutschland GmbH fka Pining Ventures GmbH Subsidiary · Germany
    • Tilray France SAS Subsidiary · France
    • and 5 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

What it owns

What Tilray reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$680.2M5 May 31, 2026$568.4M5 May 31, 2025+19.7%
Finance-lease assets$118.0M5 May 31, 2026$40.3M5 May 31, 2025+192.7%
Operating-lease assets (leased space)$42.3M5 May 31, 2026$22.3M5 May 31, 2025+89.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$226.0M5 May 31, 2026$221.7M12 May 31, 2025+1.9%
Marketable securities, current$5.3M5 May 31, 2026$34.7M12 May 31, 2025−84.8%
Long-term investments$6.6M5 May 31, 2026$10.1M5 May 31, 2025−35.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$752.4M5 May 31, 2026$752.4M5 May 31, 20250%
Intangible assets, net (excluding goodwill)$42.8M5 May 31, 2026$21.4M5 May 31, 2025+99.7%
Finite-lived intangibles, gross$58.0M5 May 31, 2026$1.6B5 May 31, 2025−96.4%
Accumulated amortization$15.2M5 May 31, 2026$343.3M5 May 31, 2025−95.6%
Finite-lived intangibles, net$42.8M5 May 31, 2026$21.4M12 May 31, 2025+99.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$301.2M5 May 31, 2026$270.9M5 May 31, 2025+11.2%

Properties, in its own words

The following outlines our principal cultivation, manufacturing, storage facilities and brewpubs by reporting segment as of May 31, 2026:

Facility and Primary Use · Location · Reporting Segment · Owned/ Leased · Approximate Square Footage

The rest of Item 2

Canada:

Aphria One (Cannabis Cultivation and Processing) · Leamington, ON · Cannabis · Owned · 1,400,000

Aphria Diamond Ltd. (Cannabis Cultivation) · Leamington, ON · Cannabis · Owned1 · 1,500,000

Broken Coast (Cannabis Cultivation) · Nanaimo, BC · Cannabis · Owned · 60,000

High Park Holdings (Cannabis 2.0 Processing) · London, ON · Cannabis · Leased · 134,000

Manitoba Harvest (Hemp Processing) · Winnipeg, MB · Wellness · Leased · 15,000

Manitoba Harvest (Hemp Processing) · St. Agathe, MB · Wellness · Owned · 35,000

Hexo Operations Inc. (Cannabis Cultivation and Processing) · Gatineau, QC · Cannabis · Owned · 1,292,000

Redecan (Cannabis Cultivation and Processing) · Fenwick, ON · Cannabis · Owned · 400,000

Redecan (Cannabis Cultivation and Processing) · Cayuga, ON · Cannabis · Owned4 · 1,644,000

United States:

SweetWater Brewery (Craft Brewery) · Atlanta, GA · Beverage · Owned · 158,000

Breckenridge Brewery (Craft Brewery) · Fort Collins, CO · Beverage · Owned · 33,000

Breckenridge Distillery (Craft Distillery) · Breckenridge, CO · Beverage · Owned · 23,000

Breckenridge Distillery Warehouse (Storage) · Denver, CO · Beverage · Owned · 75,000

Montauk Brewing Company (Brewery/Pub facility) · Montauk, NY · Beverage · Leased · 4,000

Fort Collins (Warehouse - Inactive) · Fort Collins, CO · N/A · Owned5 · 50,000

Breckenridge Brewery, LLC (Brewery/Pub facility) · Littleton, CO · Beverage · Owned · 450,000

Breckenridge Brewery, LLC (Brewpub) · Littleton, CO · Beverage · Owned · 2,500

Craft Brew Alliance, Inc. (Craft Brewery) · Portland, OR · Beverage · Owned · 82,000

BBI Acquisition Co. (Brewpub) · Breckenridge, CO · Beverage · Leased · 8,000

Blue Point Brewing Company, Inc. (Distribution) · Patchogue, NY · Beverage · Leased · 54,000

Blue Point Brewing Company, Inc. (Storage) · Patchogue, NY · Beverage · Leased · 20,000

10 Barrel Brewing (Brewpub) · Bend, OR · Beverage · Leased · 4,000

10 Barrel Brewing, LLC (Brewpub) · Portland, OR · Beverage · Leased · 8,000

10 Barrel Brewing, LLC (Storage) · Bend, OR · Beverage · Leased · 4,000

10 Barrel Brewing, LLC (Storage) · Bend, OR · Beverage · Leased · 1,930

10 Barrel Brewing, LLC (Processing / Pub facility) · Bend, OR · Beverage · Leased · 69,000

10 Barrel Brewing, LLC (Craft Brewery) · Bend, OR · Beverage · Leased · 25,000

10 Barrel Brewing Idaho, LLC (Brewpub) · Boise, ID · Beverage · Leased · 9,000

Redhook (Brewery/Pub facility) · Seattle, WA · Beverage · Leased · 13,000

Widmer (Craft Brewery) · Portland, OR · Beverage · Leased · 3,000

Terrapin Beer Company, LLC (Brewery/Pub facility) · Athens, GA · Beverage · Owned · 100,000

Terrapin Beer Company, LLC (Warehouse / Storage) · Athens, GA · Beverage · Owned · 24,000

Terrapin Beer Company, LLC (Processing / Distribution) · Athens, GA · Beverage · Leased · 68,000

Atwater Brewing (Brewpub) · Detroit, MI · Beverage · Leased3 · 20,000

Atwater Brewing (Brewpub) · Grand Rapids, MI · Beverage · Leased3 · 6,000

Atwater Brewing (Restaurant / Brewpub) · Grosse Pointe Park, MI · Beverage · Leased3 · 10,000

McKenzie River Brewing Company, LLC (Brewery/Pub facility) · Eugene, OR · Beverage · Owned · 150,000

McKenzie River Brewing Company, LLC (Restaurant / Brewpub) · Springfield, OR · Beverage · Leased · 20,000

McKenzie River Brewing Company, LLC (Processing / Distribution) · Eugene, OR · Beverage · Leased · 32,000

Revolver Brewing Company, LLC (Brewpub) · Grandbury, TX · Beverage · Leased · 32,000

BrewDog U.S. (Restaurant / Bar) · New Albany, OH · Beverage · Leased · 8,635

BrewDog U.S. (Brewpub) · Cleveland, OH · Beverage · Leased · 9,855

BrewDog U.S. (Brewpub / Restaurant) · Las Vegas, NV · Beverage · Leased · 30,000

BrewDog U.S. (Restaurant / Bar / Hotel) · Canal Winchester, OH · Beverage · Owned · 150,000

International:

Tilray EU Campus and Cultivation Site (Cannabis Cultivation and Processing) · Cantanhede, Portugal · Cannabis · Owned2 · 3,300,000

CC Pharma (Distribution Operations) · Densborn, Germany · Distribution · Owned · 70,000

Aphria RX (Cannabis Cultivation) · Neumünster, Germany · Cannabis · Owned · 65,000

FL Group Srl (Distribution Operations) · Vado Ligure, Italy · Cannabis · Leased · 4,700

ABP (Distribution Operations) · Buenos Aires, Argentina · Distribution · Leased · 10,000

Lyphe (Distribution Operations) · Farnborough, United Kingdom · Cannabis · Leased · 2,100

Lyphe (Distribution Operations) · Farnborough, United Kingdom · Cannabis · Leased · 2,100

BrewDog U.K. (Restaurant / Bar) · Birmingham, United Kingdom · Beverage · Leased · 1,400

BrewDog U.K. (Restaurant / Bar / Hotel) · Edinburgh, United Kingdom · Beverage · Leased · 25,000

BrewDog U.K. (Restaurant / Bar) · Edinburgh, United Kingdom · Beverage · Leased · 4,650

BrewDog U.K. (Restaurant / Bar) · Canary Wharf, United Kingdom · Beverage · Leased · 9,600

BrewDog U.K. (Restaurant / Bar) · London, United Kingdom · Beverage · Leased · 5,500

BrewDog U.K. (Restaurant / Bar) · London, United Kingdom · Beverage · Leased · 8,900

BrewDog U.K. (Restaurant / Bar) · London, United Kingdom · Beverage · Leased · 29,000

BrewDog U.K. (Restaurant / Bar) · Manchester, United Kingdom · Beverage · Leased · 3,000

BrewDog U.K. (Restaurant / Bar) · London, United Kingdom · Beverage · Leased · 5,500

BrewDog U.K. (Warehouse / Distribution) · Motherwell, United Kingdom · Beverage · Leased · 127,000

BrewDog U.K. (Restaurant / Bar) · Manchester, United Kingdom · Beverage · Leased · 14,600

BrewDog U.K. (Brewpub / office) · Ellon, Scotland · Beverage · Owned · 16,000

BrewDog U.K. (Restaurant / Bar) · Aberdeen, United Kingdom · Beverage · Leased · 6,600

BrewDog U.K. (Restaurant / Bar) · Bristol, United Kingdom · Beverage · Leased · 9,600

Item 2 of the 10-K filed Jul 28, 2026.17

The story

Founded in 2013, Tilray was originally incorporated under the umbrella of Seattle-based Privateer Holdings and was one of Canada's first licensed producers. At the end of 2014, it secured the first institutional investment in the cannabis industry from Founders Fund, a San Francisco-based venture capital fund. In 2016, it became the first cannabis company to conduct a clinical trial approved by Health Canada. The trial evaluated the therapeutic potential of medical cannabis. In January 2017, Tilray was certified for good manufacturing practices.

By October 2018, the company had raised $1.1 billion. In July 2018, it became the first cannabis company to trade publicly on a major U.S. stock exchange, opening on the NASDAQ exchange at a price of $17 per share, which increased in September 2018 to $214 per share, and then descended to $29 per share by August 2019. The IPO raised US$153 million.

In September 2018, Tilray became the first Canadian cannabis company to legally export medical cannabis to the U.S. for a clinical trial. In December 2018, the company signed a deal with Novartis subsidiary Sandoz to sell, distribute and co-brand Tilray's non-smokeable/non-combustible medical cannabis products in legal markets worldwide. On June 19, 2018, Tilray announced the launch of High Park Company which operates in the adult recreational cannabis market to establish unique adult-use brands in Canada.

Since September 2022, Tilray has been licensed by the Polish and Italian Ministries of Health to import and distribute THC25 medical cannabis throughout Poland and Italy.

In August 2023, Tilray acquired eight beverage brands in addition to the breweries of the brands from Anheuser-Busch for $85 million.

From Wikipedia’s article on Tilray, shared under CC BY-SA 4.0.7

Leadership

Who has led Tilray, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (19)

Products and brands

In partnership with University of Sydney, NSW Government, Chris O'Brien Lifehouse, Tilray participated in a clinical trial testing the efficacy and tolerability of medical cannabis as a possible treatment for the side effects of chemotherapy. Led by The Hospital for Sick Children, in Toronto, Canada, Tilray provided a cannabidiol (CBD) oil product available in Canada to test the efficacy and tolerability of medical cannabis oil as a possible treatment for pediatric epilepsy (Dravet syndrome). In partnership with the University of British Columbia, Tilray provided medical cannabis products used to test medical cannabis as a possible treatment for post-traumatic stress disorder. In partnership with the Grupo Español de Investigación en Neurooncología GEINO, in Spain, Tilray supplied medical cannabis products for the trial testing the efficacy and tolerability of medical cannabis as a possible treatment for glioblastoma.

In 2019, Tilray signed an agreement with Cannamedical Pharma GmbH to export $3.3 million worth of medical cannabis from its Portugal facility to Germany, marking Tilray's first export from Tilray Portugal Unipessoal, Lda. Tilray also has a research partnership with Coimbra University in Portugal.

In August 2019, Tilray announced a partnership with New York University to study the potential ability of CBD to treat alcohol use disorder and post-traumatic stress disorder. In partnership with New York University, Tilray supplied CBD for a clinical trial studying its possible efficacy for treating disorders caused by breast cancer treatments.

From Wikipedia’s article on Tilray, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • 14U Pharma GmbH Germany8
  • ABP S.A. Argentina8
  • Aphria Germany GmbH fka Nuuvera Deutschland GmbH Germany8
  • Aphria RX GMBH fka Deutschland GmbH Germany8
  • Aphria Wellbeing GmbH Germany8
  • BrewDog Brewing Australia Pty Ltd. Australia8
  • CC Pharma GmbH Germany8
  • Colcanna S.A.S. Colombia8
  • Eezy Group Ltd. United Kingdom8
  • Hampstead International, Inc. Barbados8
  • High Park Botanicals B.V. The Netherlands8
  • High Park Holdings B.V. The Netherlands8
  • Lyphe Clinic Ltd. United Kingdom8
  • Lyphe Dispensary Ltd. United Kingdom8
  • Lyphe Subco Ltd. United Kingdom8
  • Marigold Projects Limited Jamaica8
  • Nuuvera Israel Limited Israel8
  • Solana Life Group, S de R.L. Panama8
  • Tilray Australia New Zealand Pty. Ltd. Australia8
  • Tilray Beverages UK Limited United Kingdom8
  • Tilray Brands UK, Ltd. fka Tilray Wellness UK Ltd. United Kingdom8
  • Tilray Deutschland GmbH fka Pining Ventures GmbH Germany8
  • Tilray France SAS France8
  • Tilray Lyphe UK Ltd. United Kingdom8
All 28 listed subsidiaries
  • Tilray Medical Italia S.r.l. fka FL Group S.r.l. Italy8
  • Tilray Portugal Unipessoal, Lda. Portugal8
  • Tilray Ventures Limited Ireland8
  • Travel Clinic Farnborough Ltd. United Kingdom8

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

Strategic partnerships and acquisitions

In 2018, Tilray announced it had entered into global alliance with Sandoz, a division of Novartis to co-brand and distribute non-combustible medical cannabis products in global markets where it is legally authorized. The Globe and Mail dubbed this partnership as ‘big-pharma’s first foray into cannabis’.

Also in 2018, Tilray announced a $100-million joint venture with the world's largest brewer, AB InBev to research non-alcohol tetrahydrocannabinol (THC) and cannabidiol (CBD)-infused beverages, through their respective subsidiaries, Labatt Breweries and High Park Company.

In 2019, Tilray signed a $250 million revenue-sharing deal with U.S. based brand company, Authentic Brands Group, to leverage ABG brand names, such as Juicy Couture, Greg Norman, and Nine West to create cannabis products. ABG has a portfolio of over 50 brands.

In February 2019, Tilray acquired Manitoba Harvest, a hemp foods manufacturer, for $317 million from Compass Diversified Holdings. The acquisition allowed Tilray to use Manitoba Harvest's retail distribution network to enter the U.S. CBD market. Manitoba Harvest's products are available in approximately 13,000 U.S. stores and 3,600 in Canada.

Read the full text

Also in 2019, Tilray entered into an agreement with Natura Naturals Holdings which owns 155,000 square feet of licensed cultivation greenhouses in Leamington, Ontario. The acquisition doubled the cultivation ability of the company in Canada. In May 2020, Tilray announced closure of the High Park Gardens site (previously Natura Naturals) for cost reductions.

In July 2019, Tilray acquired U.K.-based Smith & Sinclair to develop CBD-infused edibles. In August 2019, Tilray acquired Alberta cannabis retailer, Four20.

On April 10, 2023, Tilray announced an agreement to acquire Hexo Corp. for approximately US$56 million. Hexo shareholders will receive 0.4352 of a share of Tilray common stock in exchange for each share held.

On March 2 2026, Tilray announced a £33m ($44.5 million) deal to acquire British brewer BrewDog's global brand, intellectual property, U.K. brewing facilities, and a network of pubs across the U.K. and Ireland. The deal covers BrewDog's core identity and physical footprint in the U.K., which includes brewing operations and 11 pubs.

Merger with Aphria

On 15 December 2020, Aphria conducted a reverse acquisition of Tilray, creating the largest global cannabis company by revenue and geographic reach. The chief executive officer (CEO) of Aphria, Irwin D. Simon, stated that the merger strategy was to capture Tilray's business assets and public trading exposure in the United States and its free trade abilities in Europe, enabling potential for becoming a global operation. Irwin was named as CEO and chairman of the board for the merged company, and Tilray CEO, Brendan Kennedy, will be a member of the board of directors. The merged companies will keep Tilray's name and trade under the Tilray ticker symbol, TLRY, on the NASDAQ exchange.

By combining assets, the new Tilray company will develop craft beer and cannabis-infused beverages in partnership with Anheuser-Busch InBev, and have branded hemp and cannabidiol products. According to one source, the world market potential for cannabis products is $94 billion by 2025.

From Wikipedia’s article on Tilray, shared under CC BY-SA 4.0.7

Former names

  • Tilray, Inc.Feb 20, 2018 to Jan 10, 20226

Timeline

  1. Oct 8, 20268-K Results of operations42
  2. Sep 14, 20268-K Unregistered sale of shares43
  3. Aug 10, 20268-K Unregistered sale of shares44
  4. Jul 28, 20268-K Results of operations45
  5. Jun 30, 20268-K Unregistered sale of shares46
  6. Jun 9, 20268-K Unregistered sale of shares47
  7. Apr 21, 20268-K Other events48
  8. Apr 15, 20268-K Unregistered sale of shares49
  9. Apr 15, 20268-K Entered a material agreement50
  10. Apr 1, 20268-K Results of operations51
  11. Mar 2, 20268-K Entered a material agreement; Completed an acquisition or sale; Other events52
  12. Jan 8, 20268-K Results of operations53
  13. May 4, 2021New chief executive Irwin D. Simon becomes CEO18
  14. Jul 18, 2018New chief executive Brendan Kennedy becomes CEO19
  15. 2013Founded Founded1

Calendar

Coming up

  1. Around Dec 19, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Oct 8, 2026Reported quarterly or annual results42
  2. Jul 28, 2026Reported quarterly or annual results45
  3. Apr 1, 2026Reported quarterly or annual results51
  4. Jan 8, 2026Reported quarterly or annual results53
  5. Oct 9, 2025Reported quarterly or annual results54
  6. Jul 28, 2025Reported quarterly or annual results55
  7. Apr 8, 2025Reported quarterly or annual results56
  8. Jan 10, 2025Reported quarterly or annual results57

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

338 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 102 major events, 129 insider forms, 2 large holders, 82 other. The latest 20:

  1. Oct 8, 202610-Q EDGAR
  2. Oct 8, 20268-K EDGAR
  3. Sep 28, 2026ARS EDGAR
  4. Sep 28, 2026DEFA14A EDGAR
  5. Sep 28, 2026DEF 14A EDGAR
  6. Sep 18, 2026PRE 14A EDGAR
  7. Sep 14, 20268-K EDGAR
  8. Aug 27, 20264 EDGAR
  9. Aug 27, 20264 EDGAR
  10. Aug 27, 20264 EDGAR
  11. Aug 27, 20264 EDGAR
  12. Aug 10, 20268-K EDGAR
  13. Aug 7, 20264 EDGAR
  14. Aug 4, 20264 EDGAR
  15. Aug 4, 20264 EDGAR
  16. Jul 31, 20264 EDGAR
  17. Jul 31, 20264 EDGAR
  18. Jul 31, 20264 EDGAR
  19. Jul 31, 20264 EDGAR
  20. Jul 31, 2026S-8 EDGAR

The 338 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 12 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 6, 2026Gendel MitchellGlobal General CounselBuy2,500$4.43$11.1KForm 4
Aug 4, 2026Merton Carl AChief Financial OfficerBuy10,000$4.62$46.2KForm 4
Aug 3, 2026FALTISCHEK DENISE MChief Strategy OfficerBuy2,500$4.78$11.9KForm 4
Apr 21, 2026Hopkinson David G.DirectorSale33,556$6.94$232.9KForm 4
Jul 31, 2025Gendel MitchellGlobal General CounselBuy6,000$0.58$3.5KForm 4
Jul 30, 2025SIMON IRWIN DPresident and CEOBuy165,000$0.61$100.7KForm 4
Jul 30, 2025Merton Carl AChief Financial OfficerBuy33,500$0.60$20.1KForm 4
Nov 15, 2024Merton Carl AChief Financial OfficerBuy26,000$1.36$35.4KForm 4
Jan 17, 2024FALTISCHEK DENISE MChief Strategy OfficerBuy10,000$2.05$20.5KForm 4
Jan 16, 2024Gendel MitchellGlobal General CounselBuy7,200$1.98$14.3KForm 4
Jan 12, 2024Gendel MitchellGlobal General CounselBuy5,400$1.87$10.1KForm 4
Jan 12, 2024SIMON IRWIN DPresident and CEOBuy53,700$1.88$101.0KForm 4
Jan 12, 2024Merton Carl AChief Financial OfficerBuy20,000$1.87$37.4KForm 4
Nov 7, 2022Kennedy BrendanDirectorSale350,000$3.78$1.3MForm 4
Oct 5, 2022Kennedy BrendanDirectorSale350,000$2.91$1.0MForm 4
Sep 6, 2022Kennedy BrendanDirectorSale350,000$3.22$1.1MForm 4
Aug 5, 2022Kennedy BrendanDirectorSale350,000$3.91$1.4MForm 4
Jul 5, 2022Kennedy BrendanDirectorSale350,000$3.09$1.1MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

Tilray has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Irwin SimonPresident, Chief Executive Officer and Chairman of the Board$2.1M$22.2M61
2026Denise FaltischekChief Strategy Officer and Head of M&A$642.7K$3.9M61
2026Mitchell GendelGlobal General Counsel and Corporate Secretary$599.9K$3.5M61
2026Carl MertonChief Financial Officer$411.7K$3.2M61
2026Roger SavellChief Administrative Officer$562.3K$3.1M61
2025Irwin SimonPresident, Chief Executive Officer and Chairman of the Board$2.0M$10.3M61
2025Denise FaltischekChief Strategy Officer and Head of M&A$621.0K$2.4M61
2025Mitchell GendelGlobal General Counsel and Corporate Secretary$579.6K$2.2M61
2025Roger SavellChief Administrative Officer$543.4K$1.8M61
2025Carl MertonChief Financial Officer$395.9K$1.6M61
2024Irwin SimonPresident, Chief Executive Officer and Chairman of the Board$1.9M$10.1M61
2024Denise FaltischekChief Strategy Officer and Head of M&A$600.0K$2.3M61
2024Mitchell GendelGlobal General Counsel and Corporate Secretary$560.0K$2.1M61
2024Roger SavellChief Administrative Officer$525.0K$2.1M61
2024Carl MertonChief Financial Officer$388.3K$1.7M61

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Tidal Investments LLC2,498,656$11.2M0.0%−65,033
Susquehanna International Group, Llp1,021,777$4.6M0.0%+479,545
Morgan Stanley995,145$4.5M0.0%+354,120
Citadel Advisors LLC868,147$3.9M0.0%+854,239
Point72 Asset Management, L.P.648,506$2.9M0.0%New
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.646,762$2.9M0.0%+159,942
Aqr Capital Management LLC512,599$2.3M0.0%+65,011
BlackRock, Inc.461,656$2.1M0.0%+38,758
UBS Group AG454,184$2.0M0.0%−198,817
Lazard Asset Management LLC394,715$1.8M0.0%New
State Street Corp384,123$1.7M0.0%+136,123
Vanguard Portfolio Management LLC348,679$1.6M0.0%−249
Stifel Financial Corp290,864$1.3M0.0%New
XTX Topco Ltd245,120$1.1M0.0%New
Swiss National Bank233,803$1.0M0.0%+3,300
Goldman Sachs Group Inc208,274$935.1K0.0%+49,342
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC208,229$934.9K0.0%+11,894
Headlands Technologies LLC160,665$721.4K0.1%−14,395
D. E. Shaw & Co., Inc.148,383$666.4K0.0%−89,388
Two Sigma Investments, LP135,870$610.1K0.0%−48,973
Jane Street Group, LLC122,860$551.6K0.0%−251,065
California State Teachers Retirement System121,719$546.5K0.0%+20,615
Northern Trust Corp110,665$496.9K0.0%−135
SIG North Trading, ULC100,407$450.8K0.1%+28,660
Lighthouse Investment Partners, LLC97,279$436.8K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 18, 2022Brian J. MastRepublican, HouseSale$1,001 - $15,000+170.6%Report
May 3, 2021Brian J. MastRepublican, HouseExchange$1,001 - $15,000Report
Feb 10, 2021Brian J. MastRepublican, HouseSale$50,001 - $100,000+197.3%Report
Feb 9, 2021Brian J. MastRepublican, HousePartial sale$15,001 - $50,000+197.0%Report
Feb 9, 2021Brian J. MastRepublican, HousePartial sale$15,001 - $50,000+197.0%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Tilray is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTilray Brands, Inc.2
  • CIK0001731348
  • Employer ID (EIN)82-431062217
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsMay 312
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address445 Park Avenue, New York, NY 100222
  • Phone519.322.88002
  • Shares outstanding147,787,523 as of Oct 6, 202614
  • Public float$900.0M as of Nov 28, 202517
  • AuditorPricewaterhouseCoopers LLP, Toronto, Canada PCAOB ID 2017; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceFeb 20, 20182
  • Filings770 in all: 4 (299), 8-K (159), DEFA14A (83), 3 (28), 10-Q (26), 424B7 (21), 8-K/A (11), 425 (10)2
    All 44 form types

    DEF 14A (10), UPLOAD (10), 10-K (9), CORRESP (9), S-8 (9), 424B5 (8), PRE 14A (8), 4/A (7), SC 13D/A (7), FWP (5), SC 13G (5), SC 13G/A (5), ARS (4), S-3ASR (4), 10-K/A (3), SC 13D (3), 424B2 (2), 424B3 (2), 424B4 (2), DRS/A (2), DRSLTR (2), EFFECT (2), S-1/A (2), 144 (1), 305B2 (1), 8-A12B (1), 8-A12B/A (1), CERT (1), CT ORDER (1), D (1), DEFM14A (1), DRS (1), PREM14A (1), S-1 (1), S-4 (1), S-4/A (1)

  • Latest filingsAnnual report (10-K) Jul 28, 2026
    Quarterly report (10-Q) Oct 8, 2026
    Proxy statement (DEF 14A) Sep 28, 2026
    Latest 8-K (8-K) Oct 8, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareTLRYNasdaq

From the cover page of the 10-K filed Jul 28, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Tilray names in Item 1A of its 10-K filed Jul 28, 2026: 62 risks under these headings, as written.17

  • Risks Related to the Cannabis Business
  • Our cannabis business is dependent upon regulatory approvals and licenses, ongoing compliance and reporting obligations, and timely renewals.
  • Government regulation of the cannabis industry is evolving, including recent regulatory developments in the United States to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act or revise the current federal framework under the 2018 Farm Bill for hemp-derived cannabis, including Delta-9, and any unfavorable changes or lack of commercial legalization could impact our ability to carry on our business as currently conducted and the potential expansion of our business.
  • Competition from the illicit cannabis market could impact our ability to succeed.
  • Our production and processing facilities are integral to our business and adverse changes or developments affecting our facilities may have an adverse impact on our business.
  • We face intense competition, and anticipate competition will increase, which could hurt our business.
  • The cannabis industry and market are relatively new and evolving, which could impact our ability to succeed in this industry and market.
  • Regulations constrain our ability to market and distribute our products in Canada and Europe.
  • Research regarding the health effects of cannabis is in relatively early stages and subject to further study which could impact demand for cannabis products.
  • United States regulations relating to cannabinoid products, including CBD, Delta-9 THC, THCA and other cannabinoids, are rapidly evolving, and recent federal and state legislative developments may materially restrict or eliminate certain product categories and adversely affect our business objectives.
  • Risks related to the Beverage Business
  • Changes in consumer preferences or public attitudes about alcohol could decrease demand for our beverage products.
The other 52 risks
  • Developments affecting production sites, including at our breweries or our distillery in Breckenridge, could negatively impact financial results for our beverage business segment.
  • Our ability to complete the BrewDog U.S. acquisition is subject to regulatory approvals, and we may face risks associated with integrating all of the acquired BrewDog businesses.
  • Sweetwater, Breckenridge, Montauk, BrewDog and our other recently-acquired craft beverage brands portfolio each face substantial competition in the beer industry and the broader market for alcoholic beverage products, which could impact our business and financial results.
  • Sweetwater, Breckenridge, Montauk, BrewDog and our other recently-acquired craft beverage brands portfolio are each dependent on distributors to deliver sustained growth and distribute products.
  • Risks Related to Ongoing Litigation Claims
  • We are subject to litigation, arbitration and demands, which could result in significant liability and costs, and impact our resources and reputation.
  • General Business Risks and Risks Related to Our Financial Condition and Operations
  • The Company’s business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.
  • Additional impairments of our goodwill, additional impairments of our intangible and other long-lived assets, and changes in the estimated useful lives of intangible assets could have a material adverse impact on our financial results.
  • We have a limited operating history and a history of net losses, and we may not achieve or maintain profitability in the future.
  • We are exposed to risks relating to the laws of various countries as a result of our international operations.
  • We are required to comply concurrently with all applicable laws in each jurisdiction where we operate or to which we export our products, and any changes to such laws could adversely impact our business.
  • Our strategic alliances and other third-party business relationships may not achieve the intended beneficial impact and expose us to risks.
  • We may not be able to successfully identify and execute future acquisitions, dispositions or other equity transactions or to successfully manage the impacts of such transactions on our operations.
  • We are subject to risks inherent in an agricultural business, including the risk of crop failure.
  • We depend on significant customers for a substantial portion of our revenue. If we fail to retain or expand our customer relationships or significant customers reduce their purchases, our revenue could decline significantly.
  • We may be unable to attract or retain key personnel, and we may be unable to attract, develop and retain additional employees required for our development and future success.
  • Increased labor costs, potential organization of our workforce, employee strikes, work stoppages, and other labor-related disruption may adversely affect our business, financial conditions and operations.
  • Significant interruptions in our access to certain supply chains for key inputs such as raw materials, aluminum, supplies, electricity, water and other utilities may impair our operations.
  • We may be negatively impacted by volatility in the political and economic environment, and a period of sustained inflation across the markets in which we operate could result in higher operating costs.
  • We face risks associated with the transportation of our products to consumers in a safe and efficient manner.
  • Our products may be subject to recalls for a variety of reasons, which could require us to expend significant management and capital resources.
  • We may be subject to product liability claims or regulatory action. This risk is exacerbated by the fact that cannabis use may increase the risk of serious adverse side effects.
  • We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception.
  • Failure to comply with safety, health and environmental regulations applicable to our operations and industry may expose us to liability and impact operations.
  • We may experience breaches of security at our facilities, which could result in product loss and liability.
  • We may be subject to risks related to our information technology systems, including service interruption, cyber-attacks and misappropriation of data, which could disrupt operations and may result in financial losses and reputational damage.
  • The cannabis industry continues to face significant funding challenges, and we may not be able to secure adequate or reliable sources of funding, which may impact our operations and potential expansion.
  • Our existing and future debt agreements may contain covenant restrictions that limit our ability to operate our business and pursue beneficial transactions.
  • Servicing our debt will require a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt.
  • Management may not be able to successfully establish and maintain effective internal controls over financial reporting.
  • Since a significant portion of our sales are generated in Canada and other countries outside the United States, fluctuations in foreign currency exchange rates could harm our results of operations.
  • We may have exposure to greater than anticipated tax liabilities, which could harm our business.
  • We may not be able to utilize our net operating loss carryforwards which could result in greater than anticipated tax liabilities.
  • We are self-insured for certain losses, which may expose us to significant unexpected costs and adversely affect our financial condition and results of operations.
  • Risks Related to Ownership of Our Securities
  • The price of our common stock in public markets has experienced and may continue to experience severe volatility and fluctuations.
  • The volatility of our stock and the stockholder base may hinder or prevent us from engaging in beneficial corporate initiatives.
  • If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.
  • Risks Related to our Convertible Securities
  • We may not have the ability to raise the funds necessary to settle conversions of the Convertible Securities in cash or to repurchase the Convertible Securities upon a fundamental change.
  • The conditional conversion feature of the Convertible Securities, if triggered, may adversely affect our financial condition and operating results.
  • Conversion of the Convertible Securities may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.
  • Certain provisions in the indentures governing the Convertible Securities may delay or prevent an otherwise beneficial takeover attempt of us.
  • Our stockholders may be subject to dilution resulting from future offerings of common stock by us.
  • Provisions in our corporate charter documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current board of directors.
  • Risks Related to our Cryptocurrency Strategy.
  • Our cryptocurrency strategy faces high risk and uncertainty in light of market volatility and an evolving regulatory landscape.
  • Risks Related to our Intellectual Property
  • We may not be able to adequately protect our intellectual property.
  • We may not realize the full benefit of the clinical trials or studies that we participate in if we are unable to secure ownership or the exclusive right to use the resulting intellectual property on commercially reasonable terms.
  • General Risk Factors
  • We may not be able to maintain adequate insurance coverage, the premiums may not continue to be commercially justifiable, and coverage limitations or exclusions may leave us exposed to uninsured liabilities.
  • The financial reporting obligations of being a public company and maintaining a dual listing on NASDAQ and on the TSX requires significant company resources and management attention.
  • As a cannabis company, we may be subject to heightened scrutiny in Canada and the United States that could materially adversely impact the liquidity of our shares of common stock.
  • Tax and accounting requirements may change in ways that are unforeseen to us and we may face difficulty or be unable to implement or comply with any such changes.
  • Geopolitical instability involving the conflict in Iran could increase fuel and energy costs in Europe and adversely affect our operations and results.

Legal proceedings

The information called for by this item is incorporated herein by reference to Note 27, Commitments and Contingencies, in the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Form 10-K.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61